A pilot study has shown that non-invasive vagus nerve stimulation (nVNS) reduced the number of headache days per month for chronic migraine patients.
News
Top three therapy areas dominate pipelines
The world’s top three therapy areas accounted for 68 percent of the overall pharmaceutical industry pipeline as of Q1 2016, according to business intelligence provider GBI Research.
Boehringer stops Giotrif head and neck trials
Boehringer Ingelheim has stopped two phase III trials for its successful lung cancer drug Giotrif (afatinib) on the advice of a data monitoring committee.
CHMP nod for Allergan’s IBS-D drug
Allergan has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Truberzi (eluxadoline) for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).
Sanofi Pasteur MSD’s four-strain flu vaccine approved
Vaccine containswo A strains and two B strains
NICE approves Servier’s Lonsurf as third-line cancer therapy
The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic colorectal cancer.
Anti-malaria drug could help fight cancer
CRUK study investigates atovaquone as an aid to radiotherapy
Shire’s pancreatic cancer drug gets EMA nod
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Shire’s Onivyde (irinotecan pegylated liposomal formulation) for approval.
Breakthrough status for Pfizer/Spark haemophilia gene therapy
Pfizer and Spark Therapeutics say their investigational haemophilia B drug SPK-9001 has been awarded breakthrough therapy status by the US Food and Drug Administration.
Study data back efficacy of AZ novel antibiotic
A late-stage study has confirmed the efficacy of AstraZeneca’s new combination antibiotic Zavicefta in patients with hospital acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).
Shire launches immunodeficiency drug for children
Shire is rolling out a paediatric indication for its immunodeficiency drug HyQvia across Europe, following a regulatory green light earlier this year.
US delay to Merck’s C.difficile antitoxin
Merck & Co’s investigational clostridium difficile treatment has been hit with a setback in the US after regulators extended the review time for the drug by three months.
Duchenne patients get NHS access to PTC’s Translarna
Cost regulators for the NHS in England and Wales have now issued final guidance recommending the use of PTC Therapeutics’ Translarna for patients with Duchenne muscular dystrophy.
Lilly’s Alimta wins NICE support
NHS use of Eli Lilly’s Alimta to treat patients with lung cancer has been endorsed in final draft guidance from the National Institute for Health and Care Excellence.
EU orphan status for Cell Medica drug
London, UK-based Cell Medica has received European Commission orphan drug designations for its lead cancer immunotherapy CMD-003 (baltaleucel-T).
